Zimelidine

DB04832

small molecule approved withdrawn

Deskripsi

Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.

Struktur Molekul 2D

Berat 317.23
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1617 Data
Cyproheptadine The therapeutic efficacy of Zimelidine can be decreased when used in combination with Cyproheptadine.
Desmopressin The risk or severity of hyponatremia can be increased when Zimelidine is combined with Desmopressin.
Ioflupane I-123 Zimelidine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Zimelidine.
Metyrosine The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Zimelidine.
Pimozide The risk or severity of QTc prolongation can be increased when Zimelidine is combined with Pimozide.
Buprenorphine Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.
Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Zimelidine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.
Hydrocodone Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.
Magnesium sulfate The therapeutic efficacy of Zimelidine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.
Orphenadrine Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.
Pramipexole Zimelidine may increase the sedative activities of Pramipexole.
Ropinirole Zimelidine may increase the sedative activities of Ropinirole.
Rotigotine Zimelidine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Zimelidine.
Sodium oxybate Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zimelidine.
Thalidomide Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Zimelidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Zimelidine.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Zimelidine.
Everolimus The metabolism of Everolimus can be decreased when combined with Zimelidine.
Flibanserin The metabolism of Flibanserin can be decreased when combined with Zimelidine.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Zimelidine.
Ivabradine The metabolism of Ivabradine can be decreased when combined with Zimelidine.
Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Zimelidine.
Lurasidone The metabolism of Lurasidone can be decreased when combined with Zimelidine.
Naloxegol The metabolism of Naloxegol can be decreased when combined with Zimelidine.
Olaparib The metabolism of Olaparib can be decreased when combined with Zimelidine.
Ranolazine The metabolism of Ranolazine can be decreased when combined with Zimelidine.
Sonidegib The metabolism of Sonidegib can be decreased when combined with Zimelidine.
Avanafil The metabolism of Avanafil can be decreased when combined with Zimelidine.
Eplerenone The metabolism of Eplerenone can be decreased when combined with Zimelidine.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Zimelidine.
Colchicine The metabolism of Colchicine can be decreased when combined with Zimelidine.
Fentanyl The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Zimelidine.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Zimelidine.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Zimelidine.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Zimelidine.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Zimelidine.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Zimelidine.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Zimelidine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Zimelidine.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Zimelidine.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Zimelidine.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Zimelidine.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Zimelidine.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Zimelidine.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Zimelidine.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Zimelidine.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Zimelidine.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Zimelidine.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Zimelidine.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Zimelidine.
Tedizolid phosphate The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Zimelidine.
Mirtazapine Zimelidine may increase the serotonergic activities of Mirtazapine.
Morphine The risk or severity of serotonin syndrome can be increased when Morphine is combined with Zimelidine.
Codeine The risk or severity of serotonin syndrome can be increased when Codeine is combined with Zimelidine.
Hydromorphone The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Zimelidine.
Oxycodone The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Zimelidine.
Butorphanol The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Zimelidine.
Dextropropoxyphene The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Zimelidine.
Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Zimelidine.
Sufentanil The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Zimelidine.
Nalbuphine The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Zimelidine.
Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Zimelidine.
Remifentanil The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Zimelidine.
Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Zimelidine.
Oxymorphone The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Zimelidine.
Dezocine The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Zimelidine.
Methadyl acetate The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Zimelidine.
Dihydroetorphine The risk or severity of serotonin syndrome can be increased when Dihydroetorphine is combined with Zimelidine.
Diamorphine The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Zimelidine.
Ethylmorphine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Zimelidine.
Etorphine The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Zimelidine.
Dextromoramide The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Zimelidine.
Desomorphine The risk or severity of serotonin syndrome can be increased when Desomorphine is combined with Zimelidine.
Carfentanil The risk or severity of serotonin syndrome can be increased when Carfentanil is combined with Zimelidine.
Dihydrocodeine The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Zimelidine.
Alphacetylmethadol The risk or severity of serotonin syndrome can be increased when Alphacetylmethadol is combined with Zimelidine.
Dihydromorphine The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Zimelidine.
Ketobemidone The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Zimelidine.
DPDPE The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Zimelidine.
Lofentanil The risk or severity of serotonin syndrome can be increased when Lofentanil is combined with Zimelidine.
Opium The risk or severity of serotonin syndrome can be increased when Opium is combined with Zimelidine.
Normethadone The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Zimelidine.
Piritramide The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Zimelidine.
Alphaprodine The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Zimelidine.
Meptazinol The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Zimelidine.
Phenoperidine The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Zimelidine.
Phenazocine The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Zimelidine.

Target Protein

Sodium-dependent serotonin transporter SLC6A4
Amine oxidase [flavin-containing] B MAOB
Amine oxidase [flavin-containing] A MAOA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 6228368
    Caille G, Kouassi E, de Montigny C: Pharmacokinetic study of zimelidine using a new GLC method. Clin Pharmacokinet. 1983 Nov-Dec;8(6):530-40.
  • PMID: 2950994
    Godbout R, Montplaisir J: The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol. 1986;9(1):46-51.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul